Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

BioMed X and AbbVie Extend Research Collaboration in the US 17-01-2023, 01:00

WillScot Mobile Mini to Participate in DA Davidson Industrials & Services Conference 15-09-2023, 07:00